Company Encyclopedia
View More
name
ClearPoint Neuro
CLPT.US
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
1.407 T
CLPT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking71/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-103.13%E
    • Profit Margin-67.40%E
    • Gross Margin63.20%A
  • Growth ScoreC
    • Revenue YoY12.83%B
    • Net Profit YoY-27.51%D
    • Total Assets YoY50.17%A
    • Net Assets YoY-45.26%E
  • Cash ScoreC
    • Cash Flow Margin-148.37%D
    • OCF YoY12.83%B
  • Operating ScoreB
    • Turnover0.68B
  • Debt ScoreD
    • Gearing Ratio73.70%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CLS Submits CE-Mark Application for ClearPoint Prism Neuro Laser Therapy System

    Clinical Laserthermia Systems AB (CLS) has submitted a CE-marking application for its ClearPoint Prism Neuro Laser Therapy System, seeking European regulatory approval for use in neurosurgery. The application follows CLS’s 2024 ISO-certification under the European Medical Device Regulation (MDR) and a successful clinical study at Skåne University Hospital. Regulatory approval is expected in the second half of 2026.

    Reuters·
    US
    CLPT
    -0.78%
    Reuters·
    US
    CLPT
    -0.78%

    ClearPoint Neuro Completes Acquisition of IRRAS

    ClearPoint Neuro has acquired IRRAS Holdings, Inc., adding IRRAflow technology to its portfolio. The deal involved $5 million in cash, 1,325,000 shares of ClearPoint Neuro stock, and a revenue-sharing arrangement. IRRAS’ operations will be included in ClearPoint Neuro’s financial results starting Q4 2025. The acquisition aims to enhance ClearPoint Neuro’s commercial scale and CNS drug delivery innovation strategy.

    Reuters·
    US
    CLPT
    -0.78%
    Reuters·
    US
    CLPT
    -0.78%

    ClearPoint Neuro’s Strategic Growth Highlighted in Earnings Call

    ClearPoint Neuro, Inc. (CLPT) held its Q3 earnings call, highlighting strategic growth despite operational challenges. The company announced a merger with IRRAS, expected to close in Q4 2025, enhancing its market presence. Q3 revenue increased by 9% to $8.9 million, with a 20% growth in neurosurgery navigation revenue. Gross margin improved to 63%, and cash reserves rose to $38.2 million. However, operating expenses increased, and revenue growth slowed due to facility transitions. ClearPoint outlined growth strategies targeting existing and new markets, with a positive outlook driven by strategic initiatives and a strong cash position.

    Tip Ranks·
    US
    CLPT
    -0.78%
    Tip Ranks·
    US
    CLPT
    -0.78%

    ClearPoint Neuro’s Q3 2025: Revenue Growth and Strategic Advances

    ClearPoint Neuro, Inc. (CLPT) reported a 9% year-over-year revenue growth to $8.9 million in Q3 2025, alongside strategic advancements such as the launch of ClearPoint Advanced Laboratories and a prototype Robotic Neuro-Navigation System. The gross margin increased to 63%, supported by higher service revenue margins. The company also secured expanded international regulatory approvals and entered a strategic acquisition agreement with IRRAS Holdings, Inc. ClearPoint aims to expand its specialized treatment centers and anticipates double-digit growth in biologics and drug delivery revenue in upcoming quarters.

    Tip Ranks·
    US
    CLPT
    -0.78%
    Tip Ranks·
    US
    CLPT
    -0.78%

    ClearPoint Neuro | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 8.861 M

    LB filings·
    US
    CLPT
    -0.78%
    LB filings·
    US
    CLPT
    -0.78%
    © 2025 Longbridge｜Disclaimer